Conclusion
tumors
TUMORS, SOLID TUMORS
In patients with pretreated advanced solid tumors, the combination of nivolumab and dose-escalated RRx-001 is safe and well-tolerated. The unconfirmed ORR and DCR are suggestive of benefit and provide a basis for further study of this regimen to determine whether it may sensitize nonimmunogenic tumors or tumors refractory to immunotherapeutic agents.